Professor Neil Scolding
Professor Neil Scolding
Inst. of Clinical Neurosciences,
Department of Neurology,
(See a map)
Telephone Number (0117) 34 06632
Neil Scolding is the Burden Professor and Director of the Bristol Institute of Clinical Neurosciences; he is currently based at Frenchay Hospital.
He trained in Neurology in Cardiff and at the National Hospital for Neurology and Neurosurgery, Queen Square, and was a University Lecturer and Consultant Neurologist in Cambridge before coming to Bristol as the Foundation Burden chairholder in 1999.
Neil has a clinical and research interest in the biology of multiple sclerosis and in particular in the clinical and experimental exploration of cell-based treatments designed to protect and repair the brain and spinal cord in patients with disability from MS. In addition, he has interests in other forms of inflammation in the nervous system, including vasculitis and sarcoidosis.
stem-cell, myelin, neurology, transplantation, regeneration, neuronal precursors
Diseases related to this field of research
Processes and functions relevant to this work
Techniques in routine use
Confocal imaging, Cell Culture
Equipment in routine use
Confocal Imaging System
- Rice, CM, Kemp, KC, Wilkins, A & Scolding, NJ 2013, Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases. Lancet, vol 382., pp. 1204-1213
- Rice, CM, Cottrell, DA, Wilkins, A & Scolding, NJ 2013, Primary progressive multiple sclerosis – progress and challenges. Journal of Neurology, Neurosurgery & Psychiatry, vol 84., pp. 1100-6
- Rice, CM, Gray, E, Hares, KM, Kemp, KC, Sun, M, Ginty, M, Barizien, S, Wilkins, A & Scolding, NJ 2013, SIRT3 expression is reduced in non-lesional grey matter in multiple sclerosis. in: Neuropathology and Applied Neurobiology., pp. 7-26
- Gray, E, Rice, C, Nightingale, H, Ginty, M, Hares, K, Kemp, K, Cohen, N, Love, S, Scolding, N & Wilkins, A 2013, Accumulation of cortical hyperphosphorylated neurofilaments as a marker of neurodegeneration in multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England), vol 19., pp. 153-161
- Hares, KM, Kemp, KC, Rice, CM, Gray, E, Scolding, NJ & Wilkins, A 2013, Reduced axonal motor protein expression in non-lesional grey matter in multiple sclerosis. Multiple Sclerosis Journal.
- Gray, E, Rice, CM, Hares, KM, Redondo, J, Kemp, KC, Williams, M, Brown, A, Scolding, NJ & Wilkins, A 2013, Reductions in neuronal peroxisomes in multiple sclerosis grey matter. Multiple Sclerosis Journal.
- Whone, AL, Kemp, K, Sun, M, Wilkins, A & Scolding, NJ 2012, Human bone marrow mesenchymal stem cells protect catecholaminergic and serotonergic neuronal perikarya and transporter function from oxidative stress by the secretion of glial-derived neurotrophic factor. Brain Research, vol 1431., pp. 86-96
- Scolding, N 2012, We are about to cure multiple sclerosis in the next 10 years, even though we do not know its cause: yes. Multiple sclerosis (Houndmills, Basingstoke, England), vol 18., pp. 782-3
- Gray, E, Ginty, M, Kemp, K, Scolding, N & Wilkins, A 2012, Peroxisome-Proliferator Activated Receptor-gamma agonists protect cortical neurons from inflammatory mediators and improve peroxisomal function. Journal of Neuroinflammation, vol 9., pp. 63 - 63
- Dey, R, Kemp, K, Gray, E, Rice, C, Scolding, N & Wilkins, A 2012, Human Mesenchymal Stem Cells Increase Anti-oxidant Defences in Cells Derived from Patients with Friedreich's Ataxia. Cerebellum (London, England), vol 11., pp. 861
Full publications list in the University of Bristol publications system